This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignee: Unversität Zürich. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Holger Moch: Innovator in Tumor-Specific Antibodies
Introduction
Holger Moch is a distinguished inventor based in Zurich, Switzerland. He has made significant contributions to the field of oncology through his innovative research and development of monoclonal antibodies.
Latest Patents
Holger Moch holds a patent for a monoclonal human tumor-specific antibody. This patent provides novel human tumor-specific antibodies, as well as fragments, derivatives, and variants that recognize the tumor-associated antigen NY-ESO-1. Additionally, it describes pharmaceutical compositions comprising such antibodies and mimics for the treatment of tumors.
Career Highlights
Holger Moch is affiliated with the University of Zurich, where he has been instrumental in advancing cancer research. His work has garnered attention for its potential impact on therapeutic strategies for tumor treatment.
Collaborations
Holger Moch collaborates with notable colleagues, including Christoph Esslinger and Sandra Künzle, who contribute to his research endeavors.
Conclusion
Holger Moch's innovative work in developing tumor-specific antibodies represents a significant advancement in cancer treatment. His contributions continue to influence the field of oncology and offer hope for improved therapeutic options.